SVNT Financial Facts
Research and development: 4.15MOther (expense) income, net: 240K
See Full Income Statement
Total current assets: 47.38M
Other current liabilities: 16.96M
See Full Balance Sheet
Savient Pharmaceuticals, Inc. (SVNT) Earnings
|
Expand Research on SVNT
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -7.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -4.8% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/7/13 | Q213 | -$0.35 | -$0.31 | -$0.04 | $6.7M | $5.84M | N/A |  | | Details | |
| 5/15/13 | Q113 | -$0.34 | -$0.31 | -$0.03 | $4.7M | $5.65M | N/A | | | Details | |
3/19/13  |
 |
Q412 | -$0.39 | -$0.44 | +$0.05 | $4.95M | $6.18M | N/A | | | Details |
| 11/8/12 |
|
Q312 | -$0.56 | -$0.48 | -$0.08 | $4.9M | $5.85M | N/A | | | Details |
| 8/8/12 |
Q212 | -$0.23 | -$0.44 | +$0.21 | $4.6M | $5.24M | N/A | | | Details | |
| 5/9/12 |
Q112 | -$0.49 | -$0.46 | -$0.03 | $3.5M | $4.59M | N/A | | | Details | |
| 2/27/12 |
|
Q411 | -$0.44 | -$0.38 | -$0.06 | $3.71M | $3.51M | N/A | | | Details |
| 11/3/11 |
|
Q311 | -$0.39 | -$0.40 | +$0.01 | $2.58M | $3.17M | N/A | | | Details |
